APA
Katz L., Gisbert J. P., Manoogian B., Lin K., Steenholdt C., Mantzaris G. J., Atreja A., Ron Y., Swaminath A., Shah S., Hart A., Lakatos P. L., Ellul P., Israeli E., Svendsen M. N., van der Woude C. J., Katsanos K. H., Yun L., Tsianos E. V., Nathan T., Abreu M., Dotan I., Lashner B., Brynskov J., Terdiman J. P., Higgins P. D. R., Chaparro M. & Ben-Horin S. (20130404). Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. : Inflammatory bowel diseases.
Chicago
Katz Lior, Gisbert Javier P, Manoogian Beth, Lin Kirk, Steenholdt Casper, Mantzaris Gerassimos J, Atreja Ashish, Ron Yulia, Swaminath Arun, Shah Somal, Hart Ailsa, Lakatos Peter Laszlo, Ellul Pierre, Israeli Eran, Svendsen Mads Naundrup, van der Woude C Janneke, Katsanos Konstantinos H, Yun Laura, Tsianos Epameinondas V, Nathan Torben, Abreu Maria, Dotan Iris, Lashner Bret, Brynskov Jorn, Terdiman Jonathan P, Higgins Peter D R, Chaparro Maria and Ben-Horin Shomron. 20130404. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. : Inflammatory bowel diseases.
Harvard
Katz L., Gisbert J. P., Manoogian B., Lin K., Steenholdt C., Mantzaris G. J., Atreja A., Ron Y., Swaminath A., Shah S., Hart A., Lakatos P. L., Ellul P., Israeli E., Svendsen M. N., van der Woude C. J., Katsanos K. H., Yun L., Tsianos E. V., Nathan T., Abreu M., Dotan I., Lashner B., Brynskov J., Terdiman J. P., Higgins P. D. R., Chaparro M. and Ben-Horin S. (20130404). Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. : Inflammatory bowel diseases.
MLA
Katz Lior, Gisbert Javier P, Manoogian Beth, Lin Kirk, Steenholdt Casper, Mantzaris Gerassimos J, Atreja Ashish, Ron Yulia, Swaminath Arun, Shah Somal, Hart Ailsa, Lakatos Peter Laszlo, Ellul Pierre, Israeli Eran, Svendsen Mads Naundrup, van der Woude C Janneke, Katsanos Konstantinos H, Yun Laura, Tsianos Epameinondas V, Nathan Torben, Abreu Maria, Dotan Iris, Lashner Bret, Brynskov Jorn, Terdiman Jonathan P, Higgins Peter D R, Chaparro Maria and Ben-Horin Shomron. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. : Inflammatory bowel diseases. 20130404.